arrow
Z

Zhongtao Zhang

national clinical research center for digestive diseases
H指数:36
被引数:4,729

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MAGI3 Acts as an Intestinal Epithelial Gatekeeper in Inflammation‐Associated Colorectal Cancer by Suppressing the STAT3‐CCL2 Axis and TAM‐Mediated Immunosuppression

MAGI3通过抑制STAT3-CCL2轴和TAM介导的免疫抑制,在炎症相关结直肠癌中作为肠道上皮的“守门人”发挥作用

2026-10-310
PRE
Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

GLP-1受体激动剂博芳鲁肽对中国成人超重或肥胖患者的疗效和安全性: 一项随机、双盲、安慰剂对照2b期试验

2026-02-270
OAAI
High-dose vitamin C: A promising anti-tumor agent, insight from mechanisms, clinical research, and challenges

赵, H.; 付, W.; 杨, X.; 张, W.; 吴, S.; 马, J.; 张, T.; 姚H.; 张, Z. 高剂量维生素C:一种有前景的抗肿瘤剂,来自机制、临床研究和挑战的见解。Genes Dis. 2025, 即将出版。 [Google Scholar] [CrossRef]

2026-01-212
OAAI
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial

Iparomlimab (QL1604) 在微卫星不稳定性高 (msi-h) 或错配修复缺陷 (dMMR) 不可切除或转移性实体瘤患者中的应用: 一项关键的单臂多中心II期试验

2024-11-110
OAAI
Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial
2024-04-089
OAAI